The cardiologist determines what size Amplatzer occluder to use by inflating a small balloon within the defect, and measuring the indentation in the balloon created by the defect. The Amplatzer ...

The notion of obliterating the LAA grew out of the knowledge that most of the systemic emboli leading to stroke in patients with AF originate from the LAA. LAA exclusion was first attempted surgically ...

Rochester, MN - A case report of a patient who suffered erosion of an Amplatzer septal-occluder device (St Jude Medical) six years after it was implanted, resulting in cardiac tamponade and ...

The Food and Drug Administration clearance and CE mark position Abbott to sell its Amplatzer Piccolo Delivery System in the U ...

At 2-year follow-up, a septal occluder device was deemed safe and effective for transcatheter closure of atrial septal defects, according to new data published in Circulation: Cardiovascular ...

A novel study by Canadian physicians reported that the BioSTAR biodegradable implant achieved comparable closure rates to the Amplatzer Septal Occluder in children with atrial septal defect. A novel ...

St. Jude Medical ($STJ) got sideswiped with an FDA safety alert over one of the company's heart plugs based on reports that it could potentially wear away tissue and ...

Abbott (NYSE: ABT) received FDA clearance for its Amplatzer Piccolo delivery system for use with the Amplatzer Piccolo ...

Abbott Laboratories ABT recently presented late-breaking data from the Amulet LAA Occluder IDE trial comparing the company's Amplatzer Amulet Left Atrial Appendage (LAA) Occluder with Boston ...

After bicuspid aortic valve, ventricular septal defects (VSDs) are the most common congenital heart abnormalities. Of all congenital defects, around 20% are solitary lesions and another 10% are ...

Perimembranous ventricular septal defects (VSDs) involving the membranous septum and the adjoining muscular septum are the most common form of congenital heart defect. Traditional surgical repair ...